Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P302)
Conditions
Interventions
TNX-102 SL
Placebo SL Tablets
Locations
30
United States
Ashild Peters
Phoenix, Arizona, United States
Ashild Peters
Little Rock, Arkansas, United States
Ashild Peters
Rogers, Arkansas, United States
Ashild Peters
Beverly Hills, California, United States
Ashild Peters
Oceanside, California, United States
Ashild Peters
Orange, California, United States
Start Date
March 7, 2019
Primary Completion Date
April 24, 2020
Completion Date
April 24, 2020
Last Updated
February 6, 2025
NCT06956781
NCT07010757
NCT07462312
NCT06804525
NCT07351305
NCT07447089
Lead Sponsor
Tonix Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions